The Pharmacokinetics of Antiviral Therapy in Paediatric Patients

Herpes

Volumn 10, Issue 3, 2003, Pages 66-71

  Eksborg, Staffan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Aciclovir; Drug dose; Famciclovir; Ganciclovirl; Immunocompromised children; Infants; Neonates; Pharmacokinetics

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

ACUTE KIDNEY TUBULE NECROSIS; BODY COMPOSITION; CHILD GROWTH; CRYSTALLURIA; DEVELOPMENT; DRUG ADMINISTRATION ROUTE; DRUG DOSE; HERPES VIRUS INFECTION; HUMAN; INTERSTITIAL NEPHRITIS; MATURATION; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; CHILD; CHILD, HOSPITALIZED; CYTOSINE; FOSCARNET; GANCICLOVIR; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; VIRUS DISEASES;

HERPESVIRIDAE;

EID: 0347285464     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Taburet AM, Singlas E. Drug interactions with antiviral drugs. Clin Phormacokinet 1996;30:385-401.
2. King JR, Kimberlin DW, Aldrovandi GM, Acosta EP. Antiretroviral pharmaco-kinetics in the paediatric population: a review. Clin Pharmacokinet 2002;41:1115-1133.
3. Shirkey HC. Drug dosage for infants and children. JAMA 1965;193:105-108.
4. Holford NHG. A size standard for pharmaco-kinetics. Clin Pharmacokinet 1996;30:329-332.
5. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M et al. Evaluation of child/adult pharmaco-kinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002;66:185-200.
6. Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmaco-kinetic-pharmacodynamic interface (Part 1). Clin Pharmacokinet 1988;14:189-216.
7. Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmaco-kinetic-pharmacodynamic interface (Part 11). Clin Pharmacokinet 1988;14:261-286.
8. Deguchi Y, Koshida R, Nakashima E, Watanabe R, Taniguchi N, Ichimura F et al. Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmaco-kinetic concepts. J Pharm Sci 1988;77:674-678.
9. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmocokinet 1990;19:280-318.
10. Yee GC, McGuire TR, Gmur DJ, Lennon TP, Deeg HJ. Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation. Influence of age, obesity, and hematocrit. Transplantation 1988;46:399-402.
11. Crom WR. Pharmacokinetics in the child. Environ Health Perspect 1994;102(Suppl 11):111-117.
12. Kanamori M, Takahashi H, Echizen H. Developmental changes in the liver weight-and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. Int J Clin Pharm Therapeutics 2002;40:485-492.
13. Kauffman RE, Kearns GL. Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin Pharmacokinet 1992;23:10-29.
14. Samara E, Granneman R. Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective. Clin Pharmacokinet 1997;32:294-312.
15. Girard P, Sheiner LB, Kastrissios H, Blaschke TF. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm 1996;24:265-282.
16. Gilman JT. Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications. Clin Pharmacokinet 1990;19:1-10.
17. Roberts RJ. Intravenous administration of medication in pediatric patients: problems and solutions. Pediatr Clin North Am 1981;28:23-34.
18. Dawson WT. Relations between age and weight and dosage of drugs. Ann Intern Med 1940;13:1594-1615.
19. Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 1982;73:186-192.
20. O'Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989;37:233-309.
21. Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52:754-772.
22. Eksborg S, Pal N, Kalin M, Palm C, Söderhäll S. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Med Pediatr Oncol 2002;38:240-246.
23. Steingrimsdottir H, Gruber A, Palm C, Grimfors G, Kalin M, Eksborg S. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob Agents Chemother 2000;44:207-209.
24. Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis 1988;157:385-388.
25. Gómez Campdera FJ, Verde E, Vozmediano MC, Valderrabano F. More about acyclovir neurotoxicity in patients on haemodialysis. Nephron 1998;78:228-229.
26. Englund JA, Fletcher CV, Balfour HH, Jr. Acyclovir therapy in neonates. J Pediatr 1991;119:129-135.
27. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983;12(Suppl B):29-37.
28. Al-Yamani MJ, Al-Khamis KI, EI-Sayed YM, Bawazir SA, Al-Rashood KA. Gouda MW. Comparative bioavailability of two tablet formulations of acyclovir in healthy volunteers. Int J Clin Pharmacol Ther 1998;36:222-226.
29. Carcao MD, Lau RC, Gupta A, Huerter H, Koren G, King SM. Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. Pediatr Infect Dis J 1998;17:626-631.
30. Tod M, Lokiec, F, Bidault R, De Bony F, Petitjean O, Aujard Y. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother 2001;45:150-157.
31. Vergin H, Kikuta C, Mascher H, Metz R. Pharmacokinetics and bioavailability of different formulations of aciclovir. Arzneimittetforschung 1995;45:508-515.
32. Nadal D. Leverger G, Sokal EM, Floret D, Perel Y, Leibundgut K et al. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. J Infect Dis 2002;186(Suppl 1): S123-S130.
33. Höglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001;47:855-861.
34. Fish DN, Vidaurri VA, Deeter RG. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids. Am J Health Syst Pharm 1999;56:1957-1960.
35. Grose C, Wiedeman J. Generic acyclovir vs. famciclovir and valacyclovir. Pediatr Infect Dis J 1997;16:838-841.
36. Dekker CL, Prober CG. Pediatric uses of valacyclovir penciclovir and famciclovir. Pediatr Infect Dis J 2001;20:1079-1082.
37. Kimberlin DW. Antiviral therapy for cytomegalovirus infections in pediatric patients. Semin Pediatr Infect Dis 2002;13:22-30.
38. Trang JM, Kidd L, Gruber W, Storch G, Demmler G, Jacobs R et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin Pharmacol Ther 1993;53:15-21.
39. Zhou X-J, Gruber W, Demmler G, Jacobs R, Reuman P, Adler S et al. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Antimicrob Agents Chemother 1996;40:2202-2205.
40. Frenkel LM, Capparelli EV, Dankner WM, Xu J, Smith IL, Ballow A et al. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. J Infect Dis 2000;182:1616-1624.
41. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999;39:800-804.
42. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002;72:142-150.